Updates on Treatment of Gemcitabine-Refractory Pancreatic Adenocarcinoma

被引：0

作者：

Makrilia, Nektaria ^{[1
]}

Syrigos, Kostas N. ^{[1
]}

Saif, Muhammad W. ^{[2
,3
]}

机构：

[1] Sotiria Gen Hosp, Athens Med School, Dept Med 3, Oncol Unit, Athens, Greece

[2] Columbia Univ Coll Phys & Surg, 177 Ft Washington Ave,Suite 6-435, New York, NY 10032 USA

[3] New York Presbyterian Hosp, Pancreas Ctr, New York, NY USA

来源：

JOURNAL OF THE PANCREAS | 2011年 / 12卷 / 04期

关键词：

capecitabine; lapatinib; Pancreatic Neoplasms; S-1; Treatment Failure;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in the treatment of refractory pancreatic cancer, as they were reported in Abstracts #e14542 and #e14588.

引用

页码：351 / 354

页数：4

共 50 条

[31] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane, C.
Okusaka, T.
Furuse, J.
Ishii, H.
Ueno, H.
Ikeda, M.
Najima, M.
Hirokawa, S.
Nakachi, K.
Ogura, T.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
[32] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
Maeda, Shimpei
Motoi, Fuyuhiko
Onogawa, Tohru
Morikawa, Takanori
Shigeru, Ottomo
Sakata, Naoaki
Takadate, Tatsuyuki
Naitoh, Takeshi
Rikiyama, Toshiki
Katayose, Yu
Egawa, Shinichi
Unno, Michiaki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 539 - 545
[33] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
Kim, Yoon Jae
Bang, Seungmin
Park, Jeong Youp
Park, Seung Woo
Chung, Jae Bock
Song, Si Young
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 529 - 533
[34] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
Yoon Jae Kim
Seungmin Bang
Jeong Youp Park
Seung Woo Park
Jae Bock Chung
Si Young Song
Cancer Chemotherapy and Pharmacology, 2009, 63 : 529 - 533
[35] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
Shimpei Maeda
Fuyuhiko Motoi
Tohru Onogawa
Takanori Morikawa
Ottomo Shigeru
Naoaki Sakata
Tatsuyuki Takadate
Takeshi Naitoh
Toshiki Rikiyama
Yu Katayose
Shinichi Egawa
Michiaki Unno
International Journal of Clinical Oncology, 2011, 16
[36] Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.
Park, Se Jun
Lee, Myung Ah
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[37] Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
Demols, A
Peeters, M
Polus, M
Marechal, R
Gay, F
Monsaert, E
Hendlisz, A
Van Laethem, JL
BRITISH JOURNAL OF CANCER, 2006, 94 (04) : 481 - 485
[38] Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols
M Peeters
M Polus
R Marechal
F Gay
E Monsaert
A Hendlisz
J L Van Laethem
British Journal of Cancer, 2006, 94 : 481 - 485
[39] The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study
Nakai, Y.
Isayama, H.
Sasaki, T.
Sasahira, N.
Hirano, K.
Tsujino, T.
Tada, M.
Kawabe, T.
Omata, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[40] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer: Is There a Standard? The Almhanna/Kim Article Reviewed
Ko, Andrew H.
ONCOLOGY-NEW YORK, 2008, 22 (10): : 1190 - +

← 1 2 3 4 5 →